Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.4556
Abstract: Importance Combination immunotherapy with nivolumab and ipilimumab has markedly improved outcomes for patients with advanced melanoma. However, these therapies pose a considerable financial burden to both patients and the health care system. The ADAPT-IT trial… read more here.
Keywords: advanced melanoma; cost; response adapted; response ... See more keywords
Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.0165
Abstract: Key Points Question Is a response-adapted strategy based on early tumor response to radiotherapy associated with improved survival with a functional larynx in patients with resectable locally advanced hypopharyngeal carcinoma? Findings In this cohort study… read more here.
Keywords: locally advanced; radiotherapy; response adapted; patients resectable ... See more keywords
Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2555
Abstract: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. read more here.
Keywords: adapted treatment; response adapted; treatment rituximab; rituximab bendamustine ... See more keywords
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.
Sign Up to like & getrecommendations! Published in 2021 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2021.100788
Abstract: Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a… read more here.
Keywords: response adapted; ineligible patients; transplant ineligible; newly diagnosed ... See more keywords
The role of response adapted therapy in the era of novel agents.
Sign Up to like & getrecommendations! Published in 2024 at "Seminars in hematology"
DOI: 10.1053/j.seminhematol.2024.06.002
Abstract: The optimal treatment of classic Hodgkin Lymphoma (cHL) requires an individualized approach, with therapy guided by pretreatment clinical risk stratification and interim response assessment with positron emission tomography (PET). The overall goal is to achieve… read more here.
Keywords: role response; novel agents; therapy; response ... See more keywords
Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1004
Abstract: Background. The FOLL12 study demonstrated that in High tumor burden patients with Follicular lymphoma (FL) treated with immunochemotherapy (ICT), standard rituximab maintenance (RM) was associated with improved Progression Free Survival (PFS) compared with a response-adapted… read more here.
Keywords: pfs; term; response; study ... See more keywords
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3591
Abstract: Mosunetuzumab (mosun) is a CD20xCD3 bispecific antibody that is active in relapsed/refractory follicular lymphoma. We designed a PET response adapted study for patients (pts) with untreated follicular lymphoma (FL) and marginal zone lymphoma (MZL) (NCT05169658).… read more here.
Keywords: treatment; part; mrd; marginal zone ... See more keywords
Response adapted oncologic surgery following neoadjuvant immunotherapy and chemotherapy for resectable locally advanced oral cavity and oropharyngeal squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e18107
Abstract: e18107 Background: Head and neck squamous cell carcinoma (SCC) is the seventh leading cause of cancer worldwide. For patients (pts) with oral cavity and oropharyngeal SCC (OSCC), surgery is the mainstay of treatment, but in… read more here.
Keywords: surgery; disease; adapted oncologic; response ... See more keywords
Optimizing frontline therapy for diffuse large B cell lymphoma (DLBCL) in older adults: A glofitamab-based, response-adapted, window-style study (GLORY).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.tps7094
Abstract: TPS7094 Background: Older adults (OA) with DLBCL classified as unfit or frail based on simplified geriatric assessment (sGA) do poorly with standard doses of anthracycline based chemotherapy. Bispecific antibodies have a preserved risk-benefit profile in… read more here.
Keywords: therapy; rate; response; study ... See more keywords